Percentage area reduction at week 4 as a prognostic indicator of complete healing in patients treated with standard of care: a post hoc analysis

被引:0
|
作者
Serena, Thomas [1 ]
Yaakov, Sadia [2 ]
Yaakov, Raphael [3 ]
King, Emily [1 ]
Driver, Vickie R. [4 ,5 ]
机构
[1] SerenaGroup Res Fdn, Cambridge, MA 02140 USA
[2] Massachusetts Coll Pharm & Hlth Sci, Boston, MA USA
[3] eKare Inc, Fairfax, VA USA
[4] Washington State Univ, Sch Med, Pullman, WA USA
[5] Wound Care Collaborat Community, Dallas, TX USA
关键词
chronic ulcers; clinical decision support; diabetic foot ulcers; percentage area reduction; surrogate endpoints; surrogate marker; topical oxygen therapy; wound; wound care; wound dressing; wound healing; DIABETIC FOOT ULCERS; TOPICAL OXYGEN-THERAPY;
D O I
暂无
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Early indicators of healing provide valuable information on the potential benefit of treatment. In patients with hard-to-heal (chronic) diabetic foot ulcers (DFUs), timely intervention is critical. Ulcers that fail to show measurable progress within four weeks of treatment are considered recalcitrant. These ulcers increase the risk of soft tissue infection, osteomyelitis and lower extremity amputation. A prognostic indicator or surrogate marker allows for rapid evaluation of treatment efficacy and safety. An inverse correlation between a percentage area reduction (PAR) of <= 50% at week 4 and complete healing by week 12 has been previously established; however, the data were derived from a standard of care (SoC) arm of clinical trials that are over a decade old. In this post hoc analysis, data from a large multicentre prospective randomised controlled trial were reviewed to assess PAR at week 4 as a prognostic indicator in patients treated with SoC. Overall, 65.4% (17/26) of patients with PAR >50% at week 4 achieved complete closure at week 12. The receiver operating characteristic (ROC) curve for area reduction by week 4 showed strong discrimination for predicting non-healing (area under the ROC curve: 0.92; p<0.001; positive predictive value: 70.6%; negative predictive value: 87.2%). These findings are consistent with previous studies and support the use of four-week PAR as a prognostic indicator.
引用
收藏
页数:6
相关论文
共 50 条
  • [41] Factors Associated with Significant Reduction in Migraine Headache Days: A Post Hoc Analysis of Phase 3 Placebo-Controlled Trials of Patients with Episodic and Chronic Migraine Treated with Galcanezumab
    Aurora, S.
    Ruff, D.
    Zhang, Q.
    Pearlman, E.
    HEADACHE, 2018, 58 : 163 - 163
  • [42] Reduction of pain and functional disability over time in patients treated with zavegepant: a post-hoc analysis of the BHV3500-301 phase 3 randomized controlled trial
    Powell, Lauren
    O'Sullivan, Fiona
    Jayasinghe, Pramoda
    Rogula, Basia
    Dai, Feng
    Cirillo, Jessica
    Sweeney, Samantha
    Abraham, Lucy
    Ailani, Jessica
    JOURNAL OF HEADACHE AND PAIN, 2025, 26 (01):
  • [43] Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study)
    Shibuki, Taro
    Mizuta, Toshihiko
    Shimokawa, Mototsugu
    Koga, Futa
    Ueda, Yujiro
    Nakazawa, Junichi
    Komori, Azusa
    Otsu, Satoshi
    Arima, Shiho
    Fukahori, Masaru
    Makiyama, Akitaka
    Taguchi, Hiroki
    Honda, Takuya
    Mitsugi, Kenji
    Nio, Kenta
    Ide, Yasushi
    Ureshino, Norio
    Shirakawa, Tsuyoshi
    Otsuka, Taiga
    BMC CANCER, 2022, 22 (01)
  • [44] Clinical outcomes and prognostic factors of patients with sepsis caused by intra-abdominal infection in the intensive care unit: a post-hoc analysis of a prospective cohort study in Korea
    Park, Chan Hee
    Lee, Jeong Woo
    Lee, Hak Jae
    Oh, Dong Kyu
    Park, Mi Hyeon
    Lim, Chae-Man
    Hong, Suk-Kyung
    BMC INFECTIOUS DISEASES, 2022, 22 (01)
  • [45] Clinical outcomes and prognostic factors of patients with sepsis caused by intra-abdominal infection in the intensive care unit: a post-hoc analysis of a prospective cohort study in Korea
    Chan Hee Park
    Jeong Woo Lee
    Hak Jae Lee
    Dong Kyu Oh
    Mi Hyeon Park
    Chae-Man Lim
    Suk-Kyung Hong
    BMC Infectious Diseases, 22
  • [46] Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab A Post Hoc Analysis of the PETACC-8 Trial
    Taieb, Julien
    Zaanan, Aziz
    Le Malicot, Karine
    Julie, Catherine
    Blons, Helene
    Mineur, Laurent
    Bennouna, Jaafar
    Tabernero, Josep
    Mini, Enrico
    Folprecht, Gunnar
    Van Laethem, Jean Luc
    Lepage, Come
    Emile, Jean-Francois
    Laurent-Puig, Pierre
    JAMA ONCOLOGY, 2016, 2 (05) : 643 - 652
  • [47] Prognostic factors for overall survival in patients with advanced digestive neuroendocrine carcinoma treated with first-line cisplatin-based chemotherapy: A post-hoc analysis of JCOG1213
    Hirano, Hidekazu
    Hirata, Kenro
    Honma, Yoshitaka
    Morizane, Chigusa
    Machida, Nozomu
    Kato, Ken
    Okusaka, Takuji
    Boku, Narikazu
    Sekine, Shigeki
    Hiraoka, Nobuyoshi
    Ogawa, Gakuto
    Sano, Yusuke
    Shibuya, Yuichi
    Takahashi, Masanobu
    Fujimori, Nao
    Nomura, Motoo
    Doki, Yuichiro
    Ueno, Makoto
    Yoshikawa, Takaki
    Takeuchi, Hiroya
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 594 - 594
  • [48] Symptomatic and Functional Remission and Recovery in Lurasidone-treated Patients with Bipolar Depression: Post-hoc Analysis of a 6-week, Placebo-Controlled Trial Followed by a 6-Month Extension
    Loebel, Antony
    Siu, Cynthia
    Rajagopalan, Krithika
    Pikalov, Andrei
    Cucchiaro, Josephine
    Ketter, Terence
    NEUROPSYCHOPHARMACOLOGY, 2014, 39 : S390 - S390
  • [49] Ramelteon 8 mg/d versus placebo in patients with chronic insomnia: Post hoc analysis of a 5-week trial using 50% or greater reduction in latency to persistent sleep as a measure of treatment effect
    Mini, Louis
    Wang-Weigand, Sherry
    Zhang, Jeff
    CLINICAL THERAPEUTICS, 2008, 30 (07) : 1316 - 1323
  • [50] Relapse Outcomes in Fingolimod-Treated Patients Previously Exposed to Natalizumab: Post-Hoc Analysis from the 4-Month, Open-Label FIRST Study
    Comi, Giancarlo
    Gold, Ralf
    Dahlke, Frank
    Sinha, Arijit
    von Rosenstiel, Philipp
    Tomic, Davorka
    Kappos, Ludwig
    NEUROLOGY, 2013, 80